Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors.

ESMO Open · 2025 · PMC12098135 · PMID 40315659

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

showed a trendP = 0.18not close (p > 0.1)

TICE showed a trend toward longer OS (57.2 versus 19.8 months; HR 0.67, 95% CI 0.37-1.2, P = 0.18) and significantly improved OS in IGCCCG intermediate-/poor-risk patients (57.2 versus 14.0 months; HR 0.44, 95% CI 0.2-0.99, P = 0.047).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.